These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 11271618)
1. [Suppression of synthesis of tumor necrosis factor]. Eigler A; Loher F; Endres S Internist (Berl); 2001 Jan; 42(1):28-34. PubMed ID: 11271618 [TBL] [Abstract][Full Text] [Related]
2. Taming TNF: strategies to restrain this proinflammatory cytokine. Eigler A; Sinha B; Hartmann G; Endres S Immunol Today; 1997 Oct; 18(10):487-92. PubMed ID: 9357141 [TBL] [Abstract][Full Text] [Related]
3. Brain injury and inflammation. A putative role of TNF alpha. Arvin B; Neville LF; Barone FC; Feuerstein GZ Ann N Y Acad Sci; 1995 Sep; 765():62-71; discussion 98-9. PubMed ID: 7486645 [No Abstract] [Full Text] [Related]
4. New indications for treatment of chronic inflammation by TNF-alpha blockade. Reimold AM Am J Med Sci; 2003 Feb; 325(2):75-92. PubMed ID: 12589232 [TBL] [Abstract][Full Text] [Related]
5. Small therapeutic molecules for the treatment of inflammatory bowel disease. van Deventer SJ Gut; 2002 May; 50 Suppl 3(Suppl 3):III47-53. PubMed ID: 11953333 [TBL] [Abstract][Full Text] [Related]
10. Type IV phosphodiesterase inhibitor is effective in prevention and treatment of experimental crescentic glomerulonephritis. Tam FW; Smith J; Agarwal S; Karkar AM; Morel D; Thompson EM; Pusey CD Nephron; 2000 Jan; 84(1):58-66. PubMed ID: 10644909 [TBL] [Abstract][Full Text] [Related]
11. Suppression of tumor necrosis factor-alpha production by interleukin-10 is enhanced by cAMP-elevating agents. Siegmund B; Eigler A; Moeller J; Greten TF; Hartmann G; Endres S Eur J Pharmacol; 1997 Feb; 321(2):231-9. PubMed ID: 9063693 [TBL] [Abstract][Full Text] [Related]